{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:05:03Z","timestamp":1789625103183,"version":"build-2803163510"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Primary ciliary dyskinesia (PCD) is a rare genetic disorder characterized by impaired ciliary function, defective mucociliary clearance, recurrent respiratory infections, and progressive respiratory morbidity. Macrolides, particularly azithromycin, have antibacterial, anti-inflammatory, and immunomodulatory properties and may therefore provide therapeutic benefit in PCD. This systematic review evaluated the efficacy and safety of macrolide therapy in patients with PCD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines and was prospectively registered in International Prospective Register of Systematic Reviews (CRD42024553793). PubMed, Scopus, Web of Science, Embase, Cochrane, and Google Scholar were searched for studies published from January 1, 1990, to June 18, 2024. Eligibility criteria were defined using the population, intervention, comparator, outcomes, and study design framework. Study selection, data extraction, and risk of bias assessment were performed independently by 3 reviewers. A meta-analysis was not performed because of substantial methodological heterogeneity across the included studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of 765 records identified, 9 studies met the inclusion criteria. These included 2 in vitro studies and 7 clinical studies, comprising case reports, case series, retrospective observational studies, and 1 randomized, placebo-controlled phase 3 trial. Across the clinical studies, sample sizes ranged from 1 to 90 participants. Overall, the available evidence suggested that macrolide therapy, particularly azithromycin, may reduce respiratory exacerbations and improve selected clinical symptoms in patients with PCD. Mechanistic in vitro evidence further indicated that azithromycin may reduce pro-inflammatory cytokine production and promote epithelial barrier repair. However, the included studies varied considerably in design, population characteristics, treatment protocols, and outcome definitions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Macrolides, especially azithromycin, may have a beneficial role in the management of PCD by reducing respiratory exacerbations, improving selected symptoms, and modulating airway inflammation. Nevertheless, the certainty of evidence remains limited by methodological heterogeneity, small sample sizes, and the scarcity of randomized controlled trials. Further large-scale, well-designed, PCD-specific clinical studies are required to confirm these preliminary findings and establish standardized treatment protocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000050263","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T17:05:20Z","timestamp":1787331920000},"page":"e50263","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the efficacy and safety of macrolide therapy in primary ciliary dyskinesia"],"prefix":"10.1097","volume":"105","author":[{"given":"Masoumeh","family":"Ghasempour Alamdari","sequence":"first","affiliation":[{"name":"Department of Pediatric Pulmonology, Bahrami Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paniz","family":"Pourpashang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Nephrology, Bahrami Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Khayatzadeh Kakhki","sequence":"additional","affiliation":[{"name":"Division of Pediatric Neurology, Bahrami Children Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malihe Sadat","family":"Rahimi Azghadi","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology, Bahrami Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufar","family":"Ghanbari","sequence":"additional","affiliation":[{"name":"Emergency Division, Bahrami Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parisa","family":"Ashournia","sequence":"additional","affiliation":[{"name":"Department of Pediatric Allergy and Clinical Immunology, Bahrami Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arezoo","family":"Akhlaghi","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Diseases, Bahrami Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5778-6444","authenticated-orcid":false,"given":"Ghazal","family":"Shariatpanahi","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Diseases, Bahrami Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260917","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.rmr.2015.10.743","article-title":"Primary ciliary dyskinesia in adults.","volume":"33","author":"Honor\u00e9","year":"2016","journal-title":"Rev Mal Respir"},{"key":"R2-20260917","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jpeds.2020.11.040","article-title":"Understanding primary ciliary dyskinesia and other ciliopathies.","volume":"230","author":"Horani","year":"2021","journal-title":"J Pediatr"},{"key":"R3-20260917","doi-asserted-by":"crossref","first-page":"9834","DOI":"10.3390\/ijms22189834","article-title":"Current and future treatments in primary ciliary dyskinesia.","volume":"22","author":"Paff","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R4-20260917","doi-asserted-by":"crossref","first-page":"1091173","DOI":"10.3389\/fped.2023.1091173","article-title":"Primary ciliary dyskinesia diagnosis and management and its implications in America: a mini review.","volume":"11","author":"Castillo","year":"2023","journal-title":"Front Pediatr"},{"key":"R5-20260917","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3390\/diagnostics11071278","article-title":"Progress in diagnosing primary ciliary dyskinesia: the North American perspective.","volume":"11","author":"O\u2019Connor","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"R6-20260917","doi-asserted-by":"crossref","first-page":"16361","DOI":"10.1038\/s41598-021-95900-z","article-title":"Therapeutic efficacy of macrolides in management of patients with mild COVID-19.","volume":"11","author":"Rashad","year":"2021","journal-title":"Sci Rep"},{"key":"R7-20260917","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1021\/acs.accounts.1c00020","article-title":"Discovery of macrolide antibiotics effective against multidrug-resistant gram-negative pathogens.","volume":"54","author":"Myers","year":"2021","journal-title":"Acc Chem Res"},{"key":"R8-20260917","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40264-019-00884-5","article-title":"Prenatal exposure to macrolides and risk of congenital malformations: a meta-analysis.","volume":"43","author":"Mallah","year":"2020","journal-title":"Drug Saf"},{"key":"R10-20260917","first-page":"CD002203","article-title":"Macrolide antibiotics (including azithromycin) for cystic fibrosis.","volume":"2","author":"Southern","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"R12-20260917","doi-asserted-by":"crossref","first-page":"446","DOI":"10.6016\/ZdravVestn.2955","article-title":"Role of macrolide antibiotics in the treatment of chronic pulmonary diseases.","volume":"89","author":"Badovinac","year":"2020","journal-title":"Zdrav Vestn"},{"key":"R13-20260917","doi-asserted-by":"crossref","first-page":"e0386022","DOI":"10.1128\/spectrum.03860-22","article-title":"Genetic adaptation and acquisition of macrolide resistance in Haemophilus spp during persistent respiratory tract colonization in chronic obstructive pulmonary disease patients receiving long-term azithromycin treatment.","volume":"11","author":"Carrera-Salinas","year":"2023","journal-title":"Microbiol Spectr"},{"key":"R14-20260917","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/TACG.S127129","article-title":"Primary ciliary dyskinesia: mechanisms and management.","volume":"10","author":"Damseh","year":"2017","journal-title":"Appl Clin Genet"},{"key":"R15-20260917","doi-asserted-by":"crossref","first-page":"E576","DOI":"10.9778\/cmajo.20200157","article-title":"Long-term macrolide therapy for chronic obstructive pulmonary disease: a population-based time series analysis.","volume":"9","author":"Yan","year":"2021","journal-title":"CMAJ Open"},{"key":"R16-20260917","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.3390\/ijms22094923","article-title":"Properties of non-aminoglycoside compounds used to stimulate translational readthrough of PTC mutations in primary ciliary dyskinesia.","volume":"22","author":"Dabrowski","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R17-20260917","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S2213-2600(20)30058-8","article-title":"Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.","volume":"8","author":"Kobbernagel","year":"2020","journal-title":"Lancet Respir Med"},{"key":"R18-20260917","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R19-20260917","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews.","volume":"14","author":"Methley","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"R20-20260917","doi-asserted-by":"crossref","first-page":"14453","DOI":"10.1038\/s41598-023-41577-5","article-title":"Azithromycin promotes proliferation and inhibits inflammation in nasal epithelial cells in primary ciliary dyskinesia.","volume":"13","author":"Varenyiova","year":"2023","journal-title":"Sci Rep"},{"key":"R21-20260917","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/jcm12010317","article-title":"Novel SPEF2 variant in a Japanese patient with primary ciliary dyskinesia: a case report and literature review.","volume":"12","author":"Mori","year":"2022","journal-title":"J Clin Med"},{"key":"R22-20260917","doi-asserted-by":"crossref","first-page":"905253","DOI":"10.3389\/fped.2022.905253","article-title":"Long-term azithromycin treatment in pediatric primary ciliary dyskinesia: a retrospective study.","volume":"10","author":"Guan","year":"2022","journal-title":"Front Pediatr"},{"issue":"suppl 62","key":"R23-20260917","first-page":"PA798","article-title":"Prophylactic azithromycin in patients with primary ciliary dyskinesia.","volume":"52","author":"Massiot","year":"2018","journal-title":"Eur Respir J"},{"key":"R24-20260917","first-page":"1093","article-title":"Two cases of primary ciliary dyskinesia showing different responses to macrolide.","volume":"51","author":"Kido","year":"2016","journal-title":"Ther Res"},{"key":"R25-20260917","first-page":"62","article-title":"Successful treatment of chronic lower respiratory tract infection by macrolide administration in a patient with intralobar pulmonary sequestration and primary ciliary dyskinesia.","volume":"15","author":"Tsubouchi","year":"2015","journal-title":"Respir Med Case Rep"},{"key":"R26-20260917","doi-asserted-by":"crossref","first-page":"9148","DOI":"10.12998\/wjcc.v10.i25.9148","article-title":"CCNO mutation as a cause of primary ciliary dyskinesia: a case report.","volume":"10","author":"Zhang","year":"2022","journal-title":"World J Clin Cases"},{"key":"R27-20260917","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thx.2005.057950","article-title":"Long-term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial.","volume":"61","author":"Clement","year":"2006","journal-title":"Thorax"},{"key":"R28-20260917","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.2010.563","article-title":"Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.","volume":"303","author":"Saiman","year":"2010","journal-title":"JAMA"},{"key":"R29-20260917","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"key":"R30-20260917","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(12)60953-2","article-title":"Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.","volume":"380","author":"Wong","year":"2012","journal-title":"Lancet"},{"key":"R31-20260917","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"key":"R32-20260917","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD.","volume":"365","author":"Albert","year":"2011","journal-title":"N Engl J Med"},{"key":"R33-20260917","doi-asserted-by":"crossref","first-page":"1093.e1","DOI":"10.1016\/j.cmi.2015.08.020","article-title":"A longitudinal study of lung bacterial pathogens in patients with primary ciliary dyskinesia.","volume":"21","author":"Alanin","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"R34-20260917","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1183\/13993003.01390-2015","article-title":"Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia.","volume":"47","author":"Ratjen","year":"2016","journal-title":"Eur Respir J"},{"key":"R35-20260917","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1165\/rcmb.2008-0357OC","article-title":"Azithromycin maintains airway epithelial integrity during Pseudomonas aeruginosa infection.","volume":"42","author":"Halldorsson","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"R36-20260917","doi-asserted-by":"crossref","first-page":"e12960","DOI":"10.14814\/phy2.12960","article-title":"The differential effects of azithromycin on the airway epithelium in vitro and in vivo.","volume":"4","author":"Slater","year":"2016","journal-title":"Physiol Rep"},{"key":"R37-20260917","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1124\/pharmrev.121.000300","article-title":"Nonantimicrobial actions of macrolides: overview and perspectives for future development.","volume":"73","author":"Kricker","year":"2021","journal-title":"Pharmacol Rev"},{"key":"R38-20260917","first-page":"39","article-title":"Treatment recommendations in primary ciliary dyskinesia.","volume":"18","author":"Polineni","year":"2016","journal-title":"Paediatr Respir Rev"},{"key":"R39-20260917","first-page":"14","article-title":"Recent advances in primary ciliary dyskinesia: from diagnosis to treatment.","volume":"6","author":"Eralp","year":"2021","journal-title":"Eur Respir Pulm Dis"},{"key":"R40-20260917","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13148-023-01430-y","article-title":"Azithromycin attenuates wheezing after pulmonary inflammation through inhibiting histone H3K27me3 hypermethylation mediated by EZH2.","volume":"15","author":"Wu","year":"2023","journal-title":"Clin Epigenetics"},{"key":"R41-20260917","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.3201\/eid2607.200017","article-title":"Macrolide-resistant Mycoplasma pneumoniae infections in pediatric community-acquired pneumonia.","volume":"26","author":"Chen","year":"2020","journal-title":"Emerg Infect Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:01:00Z","timestamp":1789624860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000050263"}},"subtitle":["A systematic review"],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":39,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000050263","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"2025-01-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}